Edis Pharma Pharmaceutical Industry, Istanbul, Turkey.
Health Science Univercity, Umraniye Training and Research Hospital, Istanbul, Turkey.
Med Gas Res. 2022 Apr-Jun;12(2):55-59. doi: 10.4103/2045-9912.326001.
The objective of this study was to provide lung disinfection by nebulizing ozone gas with distilled water and olive oil for patients who have clinical symptoms due to coronavirus disease 2019 (COVID-19). The study attempted to reduce the viral load of COVID-19 in the lungs of patients, to provide a faster response to medical treatment. Between August 2020 and September 2020, 30 patients who met the study criteria were prospectively evaluated. There were 2 groups with 15 patients in each group: patients in control group were not treated with ozone and only received standard COVID-19 treatment; patients in ozone group received lung disinfection technique with ozone and standard COVID-19 treatment. A statistically significant difference was found in the length of stay in hospital, change in C-reactive protein, polymerase chain reaction results after 5 days, and computed tomography scores between two groups. There was no statistically significant difference in D-dimer, urea, lactate dehydrogenase, lymphocyte, leukocyte, and platelet between two groups. According to the data, we think that the lung disinfection technique applied with ozone inhalation reduces the rate of pneumonia in COVID-19 patients and makes the patients respond faster to the treatment and become negative according to the polymerase chain reaction tests. The study was approved by the Ethical Committee of the Istanbul Medipol University Clinical Trials (approval No. 0011) on July 2, 2020.
本研究的目的是通过雾化含臭氧的蒸馏水和橄榄油为因 2019 冠状病毒病(COVID-19)出现临床症状的患者进行肺部消毒。本研究试图降低 COVID-19 患者肺部的病毒载量,以更快地对治疗做出反应。2020 年 8 月至 9 月,前瞻性评估了 30 名符合研究标准的患者。两组各有 15 名患者:对照组患者未接受臭氧治疗,仅接受标准 COVID-19 治疗;臭氧组患者接受臭氧和标准 COVID-19 治疗的肺部消毒技术。两组在住院时间、C 反应蛋白变化、5 天后聚合酶链反应结果和计算机断层扫描评分方面存在统计学差异。两组间的 D-二聚体、尿素、乳酸脱氢酶、淋巴细胞、白细胞和血小板无统计学差异。根据这些数据,我们认为应用臭氧吸入的肺部消毒技术降低了 COVID-19 患者肺炎的发生率,并使患者更快地对治疗做出反应,并根据聚合酶链反应检测结果转为阴性。该研究于 2020 年 7 月 2 日获得伊斯坦布尔 Medipol 大学临床试验伦理委员会(批准号 0011)的批准。